6:27 PM
 | 
Jan 29, 2013
 |  BC Extra  |  Company News

Genentech acquires Afraxis' therapeutic business

Genentech Inc. acquired from Afraxis Inc. (San Diego, Calif.) its therapeutic business, which comprises a portfolio of compounds against undisclosed, novel targets that Afraxis said covers a range of neurology, inflammation and cancer indications. Afraxis, which was founded by sole investor Avalon Ventures in 2007, is...

Read the full 218 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >